IRIS
MORGILLO, Floriana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.895
NA - Nord America 3.843
AS - Asia 1.866
SA - Sud America 211
AF - Africa 16
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 6
Totale 9.848
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.789
IE - Irlanda 1.190
IT - Italia 775
HK - Hong Kong 669
SG - Singapore 615
GB - Regno Unito 403
UA - Ucraina 401
DE - Germania 392
CN - Cina 307
FR - Francia 264
BR - Brasile 194
SE - Svezia 136
TR - Turchia 126
FI - Finlandia 112
GR - Grecia 98
CA - Canada 41
KR - Corea 37
AT - Austria 25
BE - Belgio 24
VN - Vietnam 24
PK - Pakistan 20
NL - Olanda 16
IN - India 12
CZ - Repubblica Ceca 9
MX - Messico 9
ES - Italia 7
HU - Ungheria 7
IR - Iran 7
RU - Federazione Russa 7
TW - Taiwan 7
AE - Emirati Arabi Uniti 6
AR - Argentina 6
ID - Indonesia 6
NZ - Nuova Zelanda 6
AU - Australia 5
CO - Colombia 5
EU - Europa 5
MA - Marocco 5
CH - Svizzera 4
MK - Macedonia 4
PH - Filippine 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
BD - Bangladesh 3
EG - Egitto 3
IQ - Iraq 3
PL - Polonia 3
TN - Tunisia 3
CL - Cile 2
IL - Israele 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
MY - Malesia 2
PA - Panama 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
AM - Armenia 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
EC - Ecuador 1
GA - Gabon 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
JP - Giappone 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
NO - Norvegia 1
OM - Oman 1
PE - Perù 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SC - Seychelles 1
SV - El Salvador 1
TJ - Tagikistan 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZA - Sudafrica 1
Totale 9.848
Salva come PNG Salva come JPEG
Città #
Dublin 1.182
Hong Kong 668
Chandler 662
Jacksonville 630
Santa Clara 609
Singapore 181
Princeton 164
Bremen 162
Naples 136
Medford 129
Ann Arbor 128
New York 125
Roxbury 125
Caserta 119
Wilmington 87
Beijing 81
Boardman 57
Munich 54
Nanjing 54
San Mateo 46
Woodbridge 45
Cambridge 44
Des Moines 37
Ashburn 34
Napoli 34
Los Angeles 29
Elora 28
The Dalles 25
Brussels 24
Dong Ket 24
Houston 24
Nuremberg 21
Jinan 19
Mountain View 18
São Paulo 18
Nanchang 16
Vienna 16
Seoul 15
Aiello Del Sabato 14
Düsseldorf 13
Afragola 12
Milan 12
Norwalk 12
Amsterdam 11
Aversa 11
Ercolano 11
Helsinki 11
Rome 11
Istanbul 10
Lappeenranta 10
Tianjin 10
Auburn Hills 9
Brno 9
Falkenstein 9
Shanghai 9
Bahawalpur 8
Brasília 7
Cava Dei Tirreni 7
Lanzhou 7
London 7
Rio de Janeiro 7
Venice 7
Zhengzhou 7
Giugliano in Campania 6
Guarulhos 6
Hangzhou 6
Hebei 6
Jakarta 6
Kunming 6
Piscataway 6
Shenyang 6
Somma Vesuviana 6
Belo Horizonte 5
Changchun 5
Fairfield 5
Guangzhou 5
Novara 5
Ottawa 5
Redwood City 5
Saltillo 5
Taiyuan 5
Taizhou 5
Toronto 5
Acerra 4
Anantapur 4
Marigliano 4
Ningbo 4
Padova 4
Ribeirão Preto 4
Salerno 4
Tashkent 4
Zurich 4
Andover 3
Anápolis 3
Baku 3
Bogotá 3
Bologna 3
Cercola 3
Changsha 3
Chengdu 3
Totale 6.280
Salva come PNG Salva come JPEG
Nome #
ONCOLOGIA MEDICA 153
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 113
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 113
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 99
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 98
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 96
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 96
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 92
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 90
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 89
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 89
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 88
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 87
Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication(dagger) 85
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 84
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 83
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 82
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 82
Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies 82
Chronic inflammation and oxidative stress in human carcinogenesis 81
TRASTUZUMAB RESISTANCE IN BREAST CANCER 81
AXL is an oncotarget in human colorectal cancer 80
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 79
Adequacy of Cytologic Samples by Ultrasound-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology of Peripheral Pulmonary Nodules for Morphologic Diagnosis and Molecular Evaluations: Comparison With Computed Tomography-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology 78
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 76
First-Line Erlotinib Followed by Second-Line Cisplatin- Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial 75
Farmacogenomica e cancro colorettale 75
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 73
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 72
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 72
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 72
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 72
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. 71
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 71
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 71
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 71
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 70
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 70
Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. 68
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 68
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 68
The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. 67
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials 67
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 67
Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival 67
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 67
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 66
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 66
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 66
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis 66
Combination of anti-EGFR drugs and other molecular targeted agents as anti-cancer strategy 65
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 65
Trimodality treatment in early-stage malignant pleural mesothelioma. Preliminary results of a multicenter phase II trial 65
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 65
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 65
Serum vascular endothelial growth factor (VEGF)levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 64
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib 64
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 64
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 63
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 63
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 63
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 63
PET-TC BODY CON FDG IN ONCOLOGIA 62
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 61
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? 61
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 61
Lonafarnib in cancer therapy 60
Targeting EGFR in Pancreatic Cancer Treatment. 60
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 60
It is finally time for adjuvant therapy in melanoma 60
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 60
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 59
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 59
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 59
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 59
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 59
Preoperative chemo-radiotherapy for carcinoma of the esophagus 58
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 58
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study 58
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 58
Tumori neuroendocrini (NETs) 57
Mechanisms of resistance to EGFR-targeted drugs: lung cancer 57
Immunotherapy for head and neck cancer: Present and future 57
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy 56
MEK inhibitor as a single agent and in combination with everolimus or sorafenib in a panel of colorectal cancer cell lines: implication for multitargeted approach 56
BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. 56
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 56
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 56
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. 55
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. 55
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 55
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 55
Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold! 55
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells 54
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study 54
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines 54
OPTIMIZING THERAPEUTIC COMBINATIONS OF A SELECTIVE MEK 1/2 INHIBITOR (PIMASERTIB) WITH PI3K/ MTOR INHIBITORS OR WITH MULTI-TARGETED KINASE INHIBITORS IN PIMASERTIB-RESISTANT HUMAN LUNG AND COLORECTAL CANCER CELLS 54
Metformin in lung cancer: rationale for a combination therapy 53
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 53
Erlotinib in cancer treatment 53
Totale 6.956
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.294
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.294
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202084 0 0 0 0 0 0 0 0 0 0 68 16
2020/20211.032 86 18 113 58 164 12 137 99 23 133 126 63
2021/20221.185 56 17 24 28 374 17 45 45 49 101 107 322
2022/20232.502 253 65 39 245 311 203 11 146 1.115 19 49 46
2023/2024935 82 34 43 55 291 132 18 26 16 18 74 146
2024/20252.565 33 62 30 77 453 402 397 261 438 412 0 0
Totale 10.310